Natera (NTRA) Posts Earnings Results, Misses Expectations By $0.03 EPS

Share on StockTwits

Natera (NASDAQ:NTRA) announced its quarterly earnings data on Thursday. The medical research company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.03), Briefing.com reports. The business had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. The business’s revenue for the quarter was up 16.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.51) EPS. Natera updated its FY 2018 guidance to EPS.

NASDAQ NTRA traded down $3.83 on Friday, hitting $16.80. 4,391,474 shares of the stock were exchanged, compared to its average volume of 457,138. Natera has a 52 week low of $8.60 and a 52 week high of $29.62. The firm has a market capitalization of $1.30 billion, a P/E ratio of -7.00 and a beta of 2.11.

NTRA has been the topic of several analyst reports. Zacks Investment Research raised shares of Natera from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Tuesday, July 17th. BidaskClub raised shares of Natera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 17th. Piper Jaffray Companies upped their price target on shares of Natera to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, August 9th. Craig Hallum upped their price target on shares of Natera from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Finally, TheStreet raised shares of Natera from a “d” rating to a “c-” rating in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Natera currently has a consensus rating of “Buy” and an average price target of $28.25.

In other Natera news, CEO Matthew Rabinowitz sold 185,163 shares of the company’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $25.13, for a total value of $4,653,146.19. Following the transaction, the chief executive officer now directly owns 1,701,686 shares in the company, valued at $42,763,369.18. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Steven Leonard Chapman sold 45,000 shares of the company’s stock in a transaction on Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total transaction of $1,132,200.00. Following the completion of the transaction, the chief operating officer now owns 16,628 shares in the company, valued at $418,360.48. The disclosure for this sale can be found here. Insiders have sold 2,014,988 shares of company stock worth $48,674,710 over the last ninety days. Insiders own 13.18% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. increased its holdings in shares of Natera by 7.3% in the third quarter. Alliancebernstein L.P. now owns 41,000 shares of the medical research company’s stock valued at $982,000 after purchasing an additional 2,800 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Natera by 6.9% in the third quarter. Wells Fargo & Company MN now owns 52,899 shares of the medical research company’s stock valued at $1,266,000 after purchasing an additional 3,411 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Natera by 1.5% in the first quarter. Northern Trust Corp now owns 375,674 shares of the medical research company’s stock valued at $3,483,000 after purchasing an additional 5,428 shares during the last quarter. Asymmetry Capital Management L.P. increased its holdings in shares of Natera by 4.8% in the third quarter. Asymmetry Capital Management L.P. now owns 124,517 shares of the medical research company’s stock valued at $2,981,000 after purchasing an additional 5,648 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its holdings in shares of Natera by 30.4% in the second quarter. State of Wisconsin Investment Board now owns 30,000 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 7,000 shares during the last quarter. Hedge funds and other institutional investors own 67.46% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://weekherald.com/2018/11/10/natera-ntra-posts-earnings-results-misses-expectations-by-0-03-eps.html.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Article: What factors cause inflation to rise?

Earnings History for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply